<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615962</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-001-SNG1</org_study_id>
    <nct_id>NCT04615962</nct_id>
  </id_info>
  <brief_title>Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects.</brief_title>
  <acronym>SNG100</acronym>
  <official_title>A Phase I, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability Profile of Topical Cream SNG100 for 14 Days of Treatment in Moderate Atopic Dermatitis Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seanergy Dermatology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seanergy Dermatology Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to understand better the efficacy in a randomized, double-blind,&#xD;
      intraindividual design trial in 66 participants with AD treated with SNG100, and 2 different&#xD;
      strengths of topical steroids hydrocortisone and the medium potent mometasone furoate cream.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Side Effects AE's and SAE's</measure>
    <time_frame>4 weeks</time_frame>
    <description>Evaluate safety and tolerability as measured by completion of a full prescribed treatment course, treatment interruptions, SAE's and AE's</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usability</measure>
    <time_frame>4 weeks</time_frame>
    <description>Within subject difference in response to topical product usability questionnaire items between trial treatments</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in the SCORAD index</measure>
    <time_frame>4 weeks</time_frame>
    <description>SCORAD: SCOring of Atopic Dermatitis&#xD;
Subscales:&#xD;
Eczema Spread (A): 0 - 20 Eczema Intensity (B): 0 - 63 Subjective Symptoms (C): 0 - 20 Total = (A/5) + (Bx7/2) + C Total: 0 - 103 (Higher values represent a worse outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Eczema Area and Severity Index (EASI) Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>The surface and severity of eczema is measured using the Eczema Area and Severity Index (EASI). A regional body surface area tabulation based on severity ranging from 0 (none) to 3 (severe), and severity of signs of disease, then multiplied by body area with final possible calculation ranging from 0 (none) - 72 (severe).</description>
  </other_outcome>
  <other_outcome>
    <measure>NRS score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Itch Numeric Rating Scale. 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater itch intensity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Investigator's Global Assessment (IGA) Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>The IGA measures the investigator's global assessment of the participants overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>SNG100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of low potency steroid with hydrating and moisturizing agents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This medication is used to treat skin conditions such as eczema, psoriasis, allergies, and rash.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone Acetate 1% Cream</intervention_name>
    <description>Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.</description>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate</intervention_name>
    <description>Mometasone is a medium-strength corticosteroid.</description>
    <arm_group_label>Mometasone furoate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNG100</intervention_name>
    <description>A combination of low potency steroid and skin barrier repair agent</description>
    <arm_group_label>SNG100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females 6 years old or older with a diagnosis of moderate atopic dermatitis&#xD;
             confirmed by a dermatologist&#xD;
&#xD;
          2. Any child age 6 to 18 with a diagnosis of moderate atopic dermatitis confirmed by a&#xD;
             dermatologist, together with the child's parent/guardian. Written informed consent&#xD;
             must be given by parent/guardian.&#xD;
&#xD;
          3. Capable of complying with study requirements and study procedure.&#xD;
&#xD;
          4. Investigator Global Assessment (IGA) of 3.&#xD;
&#xD;
          5. The severity of atopic dermatitis will be defined as moderate by SCORAD range of 26-50&#xD;
             and EASI range of 7.1-21 points.&#xD;
&#xD;
          6. Child-bearing potential women must use a proper contraception method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. As determined by the study doctor, a medical history that may interfere with study&#xD;
             objectives.&#xD;
&#xD;
          2. Atopic dermatitis lesions that occur only on the face and scalp.&#xD;
&#xD;
          3. Presence of a secondary infection with bacteria, fungi, or virus.&#xD;
&#xD;
          4. Recent or current participation in another research study.&#xD;
&#xD;
          5. Females who are breastfeeding, pregnant, or with plans to get pregnant during the&#xD;
             participation in the study.&#xD;
&#xD;
          6. Prior wound, tattoo, pigmentation or infection in the treated area.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuval Ramot, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Seanergy Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arik Tzour, PhD.</last_name>
    <phone>747366444</phone>
    <email>arik@miiscience.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inbal Ziv, Ms.</last_name>
    <phone>+972747366444</phone>
    <email>Inbal@miiscience.com</email>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

